SCHEMBL7047530

SCHEMBL7047530

COc1nn(-c2ccc(NC(=O)c3cccnc3)c(C)c2)c(=O)o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.60
FAAH O00519 1/20 0.60
KDM4E B2RXH2 4/20 0.55
NPC1 O15118 4/20 0.55
RAB9A P51151 3/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
TSHR P16473 3/20 0.55
ALDH1A1 P00352 2/20 0.55
HSD17B10 Q99714 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.49
LPL P06858 1/20 0.49
LIPC P11150 1/20 0.49
LIPE Q05469 1/20 0.49
CYP2C19 P33261 1/20 0.49
GFER P55789 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
POLB P06746 1/20 0.49
MAPT P10636 4/20 0.47
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7043936 0.83 MGLL (0.82) MGLLFAAHKDM4ENPC1RAB9A
SCHEMBL7571649 0.82 MGLL (0.72) MGLLFAAHKDM4ENPC1RAB9A
SCHEMBL7045989 0.79 MGLL (0.66) MGLLFAAHKDM4ENPC1RAB9A
SCHEMBL7046095 0.77 MGLL (0.74) MGLLFAAHKDM4EKMT2AALDH1A1
SCHEMBL7656723 0.77 MGLL (0.62) MGLLFAAHKDM4ENPC1RAB9A
SCHEMBL7042914 0.75 MGLL (1.00) MGLLFAAHNPC1RAB9ASMN1; SMN2
SCHEMBL7046042 0.74 MGLL (0.72) MGLLFAAHALDH1A1SMN1; SMN2LPL
SCHEMBL7044315 0.73 MGLL (0.62) MGLLFAAHMEN1KMT2ATSHR
SCHEMBL17318622 0.73 RAB9A (0.52) KDM4ENPC1RAB9AMEN1KMT2A
SCHEMBL7046148 0.73 MGLL (0.78) MGLLFAAHMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 MGLL 1542/4885FAAH 46/4885KDM4E 2956/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE MGLL 10/4885FAAH 142/4885KDM4E 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.